James Geraghty

James Arthur Geraghty was the founder of rEVO Biologics, Inc., founded in 1993, where the title held was Chairman, President & Chief Executive Officer.
Current jobs include Chairman at Catalent JNP, Inc., Chairman at Orchard Therapeutics (Europe) Ltd. since 2018, Director at Bio Ventures for Global Health since 2010, Director at Therapeutic Human Polyclonals, Inc., Independent Director at Voyager Therapeutics, Inc. since 2014, Independent Non-Executive Director at CANbridge Life Sciences Ltd. since 2017, Independent Director at Fulcrum Therapeutics, Inc. since 2016, and Independent Non-Executive Director at CANbridge Pharmaceuticals Inc. since 2018.
Former jobs include Chairman at Catalent JNP, Inc. from 2015 to 2018, Chairman at Idera Pharmaceuticals, Inc. from 2013 to 2024, Chairman at OMass Therapeutics Ltd. from 2023 to 2026, Chairman at Orchard Therapeutics Plc from 2018 to 2024, Chairman at Pieris Pharmaceuticals, Inc. from 2017 to 2024, Director at ImmuneXcite, Inc., Director at Genetix Biotherapeutics, Inc., Director at Aceragen, Inc. from 2021 to 2023, Vice President-Marketing & Strategic Planning at Caremark International, Inc., Senior Vice President-International Development at Genzyme Corp.
from 2007 to 2011, Trustee at Joslin Diabetes Center, Inc., Senior Vice President at Third Rock Ventures LLC from 2013 to 2016, President at Sanofi BV from 1998 to 2000, and Senior VP-Strategy & Business Development at Sanofi from 2012 to 2013.
Education includes graduate degrees from the University of Pennsylvania and Yale Law School, and an undergraduate degree from Georgetown University.